Consensus $227.28M.
Wednesday, May 8, 2019
ShockWave Medical reports Q1 EPS ($1.37), consensus (52c)
Reports Q1 revenue $7.3M, consensus $5.69M.
Tivity Health sees Fy19 adjusted EPS $2.24-$2.52, consensus $2.39
Raises FY19 revenue view to $1.15B-$1.18B from $612M-$627M. May not compare to consensus $612M-$627M as the updated revenue view includes revenue from the Nutrisystem acquisition.
Hanger affirms 2019 revenue outlook $1.075B-$1.105B, consensus $1.09B
Hanger reaffirms its full-year 2019 net revenue and Adjusted EBITDA outlook as follows: Revenue in a range between $1.075B and $1.105B, and adjusted EBITDA in a range between $121M and $126M.
Bio-Rad reports Q1 EPS $1.65, consensus $1.10
Reports Q1 revenue $554.0M, consensus $549.56M. “We are encouraged by our overall performance for the first quarter, which reflects continued strength in many of our product areas across most geographies. Improvements in our core operating performance during the quarter provide us with good momentum as we head into the rest of the year,” said CEO Norman Schwartz.
Biohaven Advances Late Stage Clinical Programs And Novel Targets
– Phase 2/3 clinical trials of troriluzole, a glutamate modulator, in Alzheimer’s disease, generalized anxiety disorder, and obsessive-compulsive disorder are all expected to complete enrollment by end of 2019
– Phase 2/3 clinical trial of troriluzole in Alzheimer’s disease has enrolled over 100 patients, enabling the planned futility analysis by end of 2019
– Phase 3 clinical trial of troriluzole in spinocerebellar ataxia is expected to complete enrollment by the first quarter of 2020
– Phase 3 clinical trial of verdiperstat, an oral myeloperoxidase inhibitor, in multiple system atrophy will begin enrollment in third quarter of 2019
– Ongoing non-clinical studies defined under the scientific research agreement with University of Connecticut continue to support the advancement of UC1MT
Subscribe to:
Posts (Atom)